Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Novartis ends $800 million neuroscience partnership with BioArctic.
Nov 03, 2026
Contract Type
partnership
StockholmBiotechnologyHealth Care
Description
Novartis has walked away from a neuroscience partnership worth $800 million with BioArctic just 14 months after it was signed. The decision, announced by BioArctic, is said to be unrelated to their BrainTransporter technology.
Company Information
Company
BioArctic AB
Location
Stockholm, Stockholm County, Sweden
About
BioArctic AB is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs.
Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. www.bioarctic.se
Predictive Intelligence
Strategic
ML-powered predictions for BioArctic AB's next move